Skip Navigation

A Phase 2 Study of Inotuzumab Ozogamicin NSC 772518 in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia B-ALL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02981628

Study #:
CMH - AALL1621

Start Date:
Jun 16, 2017

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02981628

View Complete Trial Details & Eligibility at ClinicalTrials.gov